Biotechnology

Activist investor PVG Asset Management is launching a full-scale proxy war to oust Anavex's board, citing a crisis of confidence and stalled progress.

A French biotech takes a critical step to industrialize a promising therapy for LCAT deficiency, navigating the high-stakes regulatory world of biologics.

NKGen Biotech is pioneering an immune therapy for neurodegeneration. But its true innovation may be a strategic pivot to Asia's fast-track regulatory pathways.

Third Arc Bio's move to fund clinical development for a new cancer drug validates Adagene's SAFEbody platform, de-risking its finances and setting the stage.

Starton Therapeutics heads to a key investor conference not with a new molecule, but a new method. Can their delivery tech turn old drugs into new blockbusters?

Frazier Life Sciences just closed a $1.1B+ oversubscribed fund. This isn't just another raise; it's a masterclass in navigating biotech volatility.

A €30M investment from the EIB and HERA is backing Ethris's novel mRNA therapeutic. Delivered via nasal spray, it aims to treat chronic respiratory ills and act as a broad-spectrum antiviral.

A landmark TGA license for Australia's first viral vector CDMO signals a strategic shift, promising to de-risk supply chains and accelerate advanced therapies.

With a key investor conference ahead, MacroGenics balances promising cancer drug data against a history of clinical setbacks and a major strategic pivot.

Dr. Timothy Donahue's new leadership at Weill Cornell while on Trethera's board highlights a key trend: integrating top clinical minds to accelerate drug development.

Karimah Es Sabar, a titan who has raised over $1.5B in bioscience, joins Linearis Ventures. This move signals a major bet on a new model for health-tech investing.

PhenoNet completes a key trial milestone for its ALS therapy, not with a new molecule, but with a repurposed drug and a savvy regulatory and operational plan.

As Aktis Oncology presents at key investor conferences, it showcases a precision miniprotein platform and a major Eli Lilly deal in a booming market.

Remix Therapeutics' hire of Nicole Sweeny is more than a new exec; it's a strategic bet on its RNA platform and a sign of the industry's maturation.

As Cardiol Therapeutics prepares for a key investor conference, it's not just a presentation; it's a test of its strategy to build a durable franchise in heart disease.

A high schooler's award-winning AI model to simulate cancer cells is more than a project; it's a blueprint for a faster, cheaper, and more humane future.

A veteran team with a pharma exit under its belt just raised $10.8M to aim AI at a notoriously tough drug target. Here’s why investors are buying the signal.

With new backing from specialist fund SCI Ventures, ViaNautis is deploying its novel gene delivery platform to develop regenerative therapies for paralysis.

With a massive cash infusion and novel brain-delivery tech, newly public Korsana Biosciences is betting it can succeed where many have failed in neurodegeneration.

With a key conference appearance, OPKO Health aims to translate its deep R&D pipeline into market confidence. Will investors buy into its long-term vision?